Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With Acute Ischemic Stroke

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With Acute Ischemic Stroke

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Borneol/edaravone (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Sponsors Simcere Pharmaceutical Group

    • Most Recent Events

    • 21 May 2024 According to a Simcere Pharmaceutical Group media release, the New Drug Application (NDA) for Sublingual Tablets of Sanbexin has been accepted by the National Medical Products Administration (NMPA) on June 28, 2023.
    • 02 Dec 2022 According to a Simcere Pharmaceutical Group media release, all treatments and visits were completed by August 2022.
    • 02 Dec 2022 Status changed from recruiting to active, no longer recruiting, according to a Simcere Pharmaceutical Group media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top